182 related articles for article (PubMed ID: 29051077)
21. Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma.
Stifter S; Babarović E; Valković T; Seili-Bekafigo I; Stemberger C; Nacinović A; Lucin K; Jonjić N
Diagn Pathol; 2010 May; 5():30. PubMed ID: 20482792
[TBL] [Abstract][Full Text] [Related]
22. The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma.
Galieni P; Travaglini F; Vagnoni D; Ruggieri M; Caraffa P; Bigazzi C; Falcioni S; Picardi P; Mazzotta S; Troiani E; Dalsass A; Mestichelli F; Angelini M; Camaioni E; Maravalle D; Angelini S; Pezzoni V
Br J Haematol; 2021 May; 193(3):542-550. PubMed ID: 33792026
[TBL] [Abstract][Full Text] [Related]
23. CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.
Chilosi M; Adami F; Lestani M; Montagna L; Cimarosto L; Semenzato G; Pizzolo G; Menestrina F
Mod Pathol; 1999 Dec; 12(12):1101-6. PubMed ID: 10619261
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma.
Scudla V; Ordeltova M; Minarik J; Dusek L; Zemanova M; Bacovsky J
Neoplasma; 2006; 53(3):213-8. PubMed ID: 16652190
[TBL] [Abstract][Full Text] [Related]
25. Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma.
Mellors PW; Binder M; Ketterling RP; Greipp PT; Baughn LB; Peterson JF; Jevremovic D; Pearce KE; Buadi FK; Lacy MQ; Gertz MA; Dispenzieri A; Hayman SR; Kapoor P; Gonsalves WI; Hwa YL; Fonder A; Hobbs M; Kourelis T; Warsame R; Lust JA; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
Blood Adv; 2020 May; 4(10):2236-2244. PubMed ID: 32442300
[TBL] [Abstract][Full Text] [Related]
26. Robust isolation of malignant plasma cells in multiple myeloma.
Frigyesi I; Adolfsson J; Ali M; Christophersen MK; Johnsson E; Turesson I; Gullberg U; Hansson M; Nilsson B
Blood; 2014 Feb; 123(9):1336-40. PubMed ID: 24385542
[TBL] [Abstract][Full Text] [Related]
27. A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients.
Kuranda K; Berthon C; Dupont C; Wolowiec D; Leleu X; Polakowska R; Jouy N; Quesnel B
Exp Hematol; 2010 Feb; 38(2):124-31. PubMed ID: 19948206
[TBL] [Abstract][Full Text] [Related]
28. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma.
Gonsalves WI; Timm MM; Rajkumar SV; Morice WG; Dispenzieri A; Buadi FK; Lacy MQ; Dingli D; Leung N; Kapoor P; Kyle RA; Gertz MA; Kumar SK
Leuk Res; 2016 May; 44():32-9. PubMed ID: 26994849
[TBL] [Abstract][Full Text] [Related]
29. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
30. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.
Matsue K; Matsue Y; Kumata K; Usui Y; Suehara Y; Fukumoto K; Fujisawa M; Narita K; Takeuchi M
Hematol Oncol; 2017 Sep; 35(3):323-328. PubMed ID: 27140172
[TBL] [Abstract][Full Text] [Related]
31. Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis.
Martello M; Remondini D; Borsi E; Santacroce B; Procacci M; Pezzi A; Dico FA; Martinelli G; Zamagni E; Tacchetti P; Pantani L; Testoni N; Marzocchi G; Rocchi S; Zannetti BA; Mancuso K; Cavo M; Terragna C
Leukemia; 2016 Sep; 30(9):1869-76. PubMed ID: 27074969
[TBL] [Abstract][Full Text] [Related]
32. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
Martín P; Santón A; Bellas C
Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
[TBL] [Abstract][Full Text] [Related]
33. Substratification of patients with newly diagnosed standard-risk multiple myeloma.
Binder M; Rajkumar SV; Ketterling RP; Dispenzieri A; Lacy MQ; Gertz MA; Buadi FK; Hayman SR; Hwa YL; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Gonsalves WI; Kyle RA; Kumar SK
Br J Haematol; 2019 Apr; 185(2):254-260. PubMed ID: 30768679
[TBL] [Abstract][Full Text] [Related]
34. Bone marrow Ki-67 index is of prognostic value in newly diagnosed multiple myeloma.
Atrash S; Robinson M; Taneja A; Paul B; Cassetta K; Ndiaye A; Varga C; Block J; Lipford EH; Smith ET; McCall CM; Thurston V; Foureau D; Usmani SZ; Voorhees PM; Bhutani M
Eur J Haematol; 2023 Sep; 111(3):373-381. PubMed ID: 37311695
[TBL] [Abstract][Full Text] [Related]
35. Double CD38
Mykytiv V; Alwaheed A; Mohd Hashim NA
Hematol Oncol Stem Cell Ther; 2019 Mar; 12(1):64-66. PubMed ID: 29079129
[TBL] [Abstract][Full Text] [Related]
36. MUC1 (EMA) expressing plasma cells in bone marrow infiltrated by plasma cell myeloma.
Baldus SE; Palmen C; Thiele J
Histol Histopathol; 2007 Aug; 22(8):889-93. PubMed ID: 17503346
[TBL] [Abstract][Full Text] [Related]
37. The Revised International Staging System Compared to the Classical International Staging System Better Discriminates Risk Groups among Transplant-Ineligible Multiple Myeloma Patients.
Bila J; Jelicic J; Dencic Fekete M; Trajkovic G; Sretenovic A; Perunicic Jovanovic M; Antic D; Mihaljevic B
Oncol Res Treat; 2017; 40(10):616-620. PubMed ID: 28950269
[TBL] [Abstract][Full Text] [Related]
38. Syndecan-1 in multiple myeloma: relationship to conventional prognostic factors.
Aref S; Goda T; El-Sherbiny M
Hematology; 2003 Aug; 8(4):221-8. PubMed ID: 12911939
[TBL] [Abstract][Full Text] [Related]
39. [Expression and clinical significance of Notch1 on the membrane of bone marrow CD38(+)CD138(+) plasma cells in the patients with multiple myeloma].
Zhao YR; Fu R; Guan J; Gao S; Liu H; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Wu YH; Song J; Wang HQ; Xing LM; Wang J; Li LJ; Shao ZH
Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):274-7. PubMed ID: 22781716
[TBL] [Abstract][Full Text] [Related]
40. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]